Showing results (1-10 of 18) with videos related to
Sort By:
Pageof 2
Journal of Pharmacokinetics and Pharmacodynamics|June 21, 2011
Bounded outcome score modeling: application to treating psoriasis with ustekinumabChuanpu Hu, Newman Yeilding, Hugh M Davis, et al.Journal of Pharmacokinetics and Pharmacodynamics|February 18, 2011
Informative dropout modeling of longitudinal ordered categorical data and model validation: application to exposure-response modeling of physician's global assessment score for ustekinumab in patients with psoriasisChuanpu Hu, Philippe O Szapary, Newman Yeilding, et al.Journal of Clinical Pharmacology|November 26, 2009
Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasisHonghui Zhou, Chuanpu Hu, Yaowei Zhu, et al.The New England Journal of Medicine|February 9, 2007
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasisGerald G Krueger, Richard G Langley, Craig Leonardi, et al.Journal of the American Academy of Dermatology|July 6, 2010
Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendationsMark Lebwohl, Newman Yeilding, Philippe Szapary, et al.Journal of Clinical Pharmacology|January 31, 2009
Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasisYaowei Zhu, Chuanpu Hu, Ming Lu, et al.Lancet (London, England)|May 20, 2008
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)Craig L Leonardi, Alexa B Kimball, Kim A Papp, et al.Annals of the New York Academy of Sciences|March 26, 2011
Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectivesNewman Yeilding, Philippe Szapary, Carrie Brodmerkel, et al.Annals of the New York Academy of Sciences|July 25, 2012
Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives--an updateNewman Yeilding, Philippe Szapary, Carrie Brodmerkel, et al.Journal of the American Academy of Dermatology|October 25, 2011
Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasisAlexa B Kimball, Philippe Szapary, Ulrich Mrowietz, et al.Pageof 2